...
首页> 外文期刊>Critical care medicine >High-osmolarity saline in neurocritical care: Systematic review and meta-analysis
【24h】

High-osmolarity saline in neurocritical care: Systematic review and meta-analysis

机译:神经重症监护中的高渗盐水:系统评价和荟萃分析

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: Intracranial hypertension and cerebral edema are known contributors to secondary brain injury and to poor neurologic outcomes. Small volume solutions of exceedingly high osmolarity, such as 23.4% saline, have been used for the management of intracranial hypertension crises and as a measure to prevent or reverse acute brain tissue shifts. We conducted a systematic literature review on the use of 23.4% saline in neurocritically ill patients and a meta-analysis of the effect of 23.4% saline on intracranial pressure reduction. DESIGN: We searched computerized databases, reference lists, and personal files to identify all clinical studies in which 23.4% saline has been used for the treatment of neurocritical care patients. Studies that did not directly involve either effects on cerebral hemodynamics or the treatment of patients with clinical or radiographic evidence of intracranial hypertension and/or cerebral swelling were eliminated. MEASUREMENTS AND MAIN RESULTS: We identified 11 clinical studies meeting eligibility criteria. A meta-analysis was performed to evaluate the percent decrease in intracranial pressure and the 95% confidence intervals, from baseline to 60 minutes or nadir from the six studies from which this information could be extracted. A fixed effects meta-analysis estimated that the percent decrease in intracranial pressure from baseline to either 60 minutes or nadir after administration of 23.4% saline was 55.6% (se 5.90; 95% confidence interval, 43.99-67.12; p < 0.0001). CONCLUSIONS: Highly concentrated hypertonic saline such as 23.4% provides a small volume solution with low cost and an over 50% reduction effect on raised intracranial pressure. Side effects reported are minor overall in view of the potentially catastrophic event that is being treated. High quality data are still needed to define the most appropriate osmotherapeutic agent, the optimal dose, the safest and most effective mode of administration and to further elucidate the mechanism of action of 23.4% saline and of osmotherapy in general.
机译:背景与目的:颅内高压和脑水肿是继发性脑损伤和不良神经系统结果的已知原因。渗透压过高的小体积溶液(例如23.4%的盐水)已用于处理颅内高压危机,并作为预防或逆转急性脑组织移位的措施。我们对神经重症患者使用23.4%生理盐水进行了系统的文献综述,并对23.4%生理盐水对颅内压降低的影响进行了荟萃分析。设计:我们搜索了计算机化的数据库,参考文献列表和个人文件,以识别其中23.4%的盐水已用于治疗神经重症患者的所有临床研究。消除了既不直接影响脑血流动力学的影响,也没有治疗具有颅内高压和/或脑肿胀的临床或放射学证据的患者的研究。测量和主要结果:我们鉴定了11项符合入选标准的临床研究。进行了荟萃分析,以评估从基线到60分钟或最低点的六项研究中颅内压降低的百分比和95%置信区间,可以从中提取此信息。一项固定作用的荟萃分析估计,给予23.4%生理盐水后,颅内压从基线下降至60分钟或最低点的百分比为55.6%(se 5.90; 95%置信区间为43.99-67.12; p <0.0001)。结论:高浓度高渗盐水(如23.4%)可提供低成本的小体积溶液,并且对颅内压升高的缓解作用可超过50%。考虑到正在治疗的潜在灾难性事件,报告的副作用总体较小。仍然需要高质量的数据来确定最合适的渗透治疗剂,最佳剂量,最安全和最有效的给药方式,并进一步阐明23.4%生理盐水和渗透疗法的作用机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号